DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems

Doximity (DOCS) expanded its AI tools to NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine, including Doximity Ask and Scribe. DOCS stock rose 0.4% post-announcement but is down 24.7% year-to-date. The collaboration aims to integrate AI into clinical workflows, potentially boosting DOCS's growth prospects. DOCS has a market cap of $5.95 billion.

Original reporting
Published Nov 16, 2026, 4:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 5:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems — source image
Decision brief

The 30-second read

$DOCSBullishLow
01

Why it matters

The expanded collaboration could increase product usage and open doors to additional hospital systems, supporting longer‑term growth.

02

Market read

First‑report of a modest partnership that nudges DOCS shares higher; limited immediate trading impact but reinforces AI‑health sector narrative.

03

What to watch

Potential integration challenges with Epic EHR and competition from other AI health platforms.

Relevance 4/10Novelty 4/10Timing: pre‑market today

Background

Doximity (DOCS) provides a digital platform for physicians, recently adding AI tools for decision support and documentation.

Company-level read

Ticker impact

$DOCSBullishHigh confidence
Context

Doximity announced an expanded AI‑clinical decision support and documentation partnership with NewYork‑Presbyterian, Columbia University and Weill Cornell Medicine.

Expected impact

likely modest upward pressure as investors price in expanded enterprise adoption

Evidence & confidence

The announcement is the first report of the expanded collaboration and the stock already inched up 0.4% on the news.

Market effects

Highlights growing demand for AI‑enabled clinical decision support in U.S. health systems.

Positive for U.S. healthcare technology providers.

Limited to AI‑healthcare niche; no broad market effect.

Counterpoint

The modest scale of the deal may not materially move revenue, limiting upside.

Key entities

  • NewYork-Presbyterian

    Partner in the AI tool rollout.

  • Columbia University

    Partner in the AI tool rollout.

  • Weill Cornell Medicine

    Partner in the AI tool rollout.

Related articles

Med

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

$DOCSMedAI 8/10

DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

$DOCSMedAI 8/10

Doximity Q2 Earnings Call Highlights

Doximity (DOCS) reported Q2 earnings, raising fiscal 2027 revenue guidance to $678M-$683M. AI Search revenue is expected to ramp gradually. Health system clients grew to 190, including 10 of the top 20 hospitals. Non-GAAP EPS was $0.36, with $713M in cash. Management discussed AI monetization and adoption challenges.

$DOCSMedAI 8/10

Doximity Earnings Call Highlights AI Growth and Guidance

Doximity (DOCS) reported Q2 revenue of $175M (+4% YoY), beating expectations. Adjusted EBITDA was $89M (51% margin), exceeding guidance. AI initiatives drove growth, with expanded health-system adoption and improved AI economics. Revenue guidance raised to $678M-$683M for 2027. Challenges include modest growth, margin pressure, and AI-search return uncertainty.